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1. Introduction 
Plasmalogens (Pls) belong to a subclass of glycerophospholipids, and widely distributed in 
human and animal tissues (Nagan & Zoeller, 2001). Although the clinical significance of 
these phospholipids is recognized in relation to peroxisomal disorders (Wanders & 
Waterham, 2006), the physiopathological roles of Pls are not fully understood. Recently, 
serum (or plasma) Pls have gained interest in several clinical symptoms of life-style related 
disease possibly because of their antioxidant properties (Brites et al., 2004). We have 
developed a highly sensitive and simple method to determine the serum concentrations of 
choline (PlsCho) and ethanolamine plasmalogen (PlsEtn) separately, using a radioactive 
iodine and high-performance liquid chromatography (125I-HPLC method) (Maeba & Ueta, 
2004; Maeba et al, 2012). The method has improved as auto-analytical system by introducing 
online detection with flow Ǆ-counter. We have applied the system to the determination of 
serum Pls from normal subjects and CAD patients, and investigated the clinical significance 
of serum Pls as a biomarker for metabolic syndrome and atherosclerosis. This chapter briefly 
describes Pls structure, distribution, functions, and biosynthesis, and describes in detail the 
methods for measurement of Pls and clinical significance of serum Pls. 
2. Plasmalogens (Pls) 
Pls are one of the three subclasses of glycerophospholipids, and characterized by a vinyl-ether 
bond (-O-CH=CH-) in sn-1 and an ester bond in sn-2 position of the glycerol backbone (Fig.1).  
 
Fig. 1. Chemical structure of Pls 
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Pls constitute 18% of the total phospholipids mass in humans, mostly as membrane 
structure component. The polar head group of Pls mainly consists of choline or 
ethanolamine. Ethanolamine plasmalogens (PlsEtn) are predominantly distributed in almost 
organs, tissues and cells except heart and blood plasma, in which PlsEtn and choline 
plasmalogens (PlsCho) are equally contained. Pls are abundantly distributed in brain, heart, 
kidney, lung, testis, skeletal muscle, erythrocyte, macrophage, and lymphocytes in human 
body. These organs, tissues, and cells are characterized by the frequent occurrence of cell 
membrane fusion or oxidative stress. 
2.1 Functions and biosynthesis of Pls 
Major functions of Pls are shown in Fig.2. 1) Modulating membrane fluidity is essential for 
regulating membrane protein functions, as well as cell fusion, exocytosis, and endocytosis. 
This function is derived from high propensity of PlsEtn to form locally inverse hexagonal 
phase in phospholipid bilayer membranes (Glaser & Gross, 1994). 2) Endogenous 
antioxidant function of Pls is derived from the presence of vinyl ether double bond, which is 
capable of scavenging free radicals (Zoeller et al., 1988). In addition, we have recently found 
a novel antioxidant function of PlsEtn to lower the susceptibility of cholesterol in 
phospholipid bilayer and membranes to oxidation, probably through modulating the 
physical property of membranes (Maeba & Ueta, 2003a, 2003b). 3) The function of storage of 
bioactive lipid source comes from the fact that the lipid mediator producing fatty acids such 
as arachidonic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) are 
preferentially located at sn-2position of Pls. 
  1. Membrane modulator 
   membrane fluidity, membrane fusion 
  2. Endogenous antioxidant 
   radical scavenger 
   lower susceptibility of cholesterol and membranes to oxidation 
  3. Storage of bioactive lipid source 
   arachidonic acid, DHA, EPA 
Fig. 2. Major functions of Pls 
Next, dihydroxyacetone phosphate (DHAP) is a starting material for biosynthesis of Pls. 
DHAP-acyltransferase (DHAP-AT) and alkyl DHAP synthase (ADHAP-S) are responsible 
for the 1st and 2nd steps of Pls biosynthesis, respectively, and are localized in peroxisome 
(Fig.3). Therefore, peroxisomal disorders often show Pls deficiency (Wanders & Waterham, 
2006). Mental retardation represents a phenotype of peroxisomal disorders, suggesting the 
essential role of Pls in the normal function of central nervous system (CNS). This is 
supported by Pls-deficient mouse, which revealed severe phenotypic alterations, including 
defects in CNS myelination (Gorgas et al., 2006). In addition to peroxisomal disorders, 
decreased brain Pls content has been reported in a number of neurological disorders such as 
spinal cord injury, Alzheimer’s disease, Down syndrome, and multiple sclerosis (Lessig & 
Fuchs, 2009). The final step of PlsEtn biosynthesis is the desaturation of 1-alkyl-2-acyl-GPE 
via the action of Δ1 desaturase, whereas PlsCho is primarily formed from PlsEtn via polar-
head group modification, by which mechanism remains still obscure (Lee, 1998). Facilitation 
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of PlsCho biosynthesis is presumably important to prevent from atherogenic status, as 
described later, therefore elucidation of the regulatory mechanism of transfer from PlsEtn to 
PlsCho must become important. 
 
Fig. 3. Biosynthetic pathway of Pls 
2.2 Quantification of Pls 
Analytical methods for Pls have been developed principally based on acid labile property of 
the vinyl-ether linkage of Pls, which leads to the sequential decomposition into fatty 
aldehydes and 1-lysophospholipids. The resultant fatty aldehydes are usually measured as 
dimethyl acetal derivatives using gas chromatography/mass spectrometry (GC/MS) 
(Ingrand et al., 2000), and 1-lysophospholipids are measured by two-dimensional thin layer 
chromatography (TLC) (Horrocks, 1968). However, these methods are laborious and 
insufficient to accurately quantify Pls in a small amount of serum (or plasma).  
2.2.1 LC/MS analysis of Pls 
Recently, LC/MS has been applied to the analysis of Pls at the molecular species levels 
(Zemski & Murphy, 2004). We also have established the analytical method for Pls molecular 
species with UPLC-MS/MS (Fig.4). 
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Fig. 4. UPLC-MS/MS analysis of PlsEtn 16:0 molecular species 
The long chain fatty alcohol in sn-1 position consists almost exclusively of 16:0, 18:0, and 
18:1 alkenyl groups, while sn-2 position is esterified predominantly with n-6 or n-3 series 
polyunsaturated fatty acids. LC/MS analysis is powerful method to provide substantial 
useful information, but the excess data is unlikely suitable for a routine diagnostic test, 
except for specific diagnostic molecular species for particular disorders such as Alzheimer’s 
disease (Goodenowe et al, 2007). 
2.2.2 
125
I-HPLC method for determination of Pls 
We have originally developed a unique method to determine total amounts of PlsCho  
and PlsEtn separately, using radioactive iodine (125I) and high-performance liquid 
chromatography (125I-HPLC method) (Maeba & Ueta, 2004; Maeba et al, 2012). The method is 
based on the binding specificity of iodine to Pls. Triiodide (1-) ion (I3-) specifically reacts with a 
vinyl-ether double bond of Pls at molar ratio 1:1 in methanol solution. Pls assay based on this 
principle had already been established (Williams et al., 1962). However, the “cold” iodine 
method has some problems of low detectable Pls and interfering substances in the extracted 
lipids from biomaterials like serum. 125I-HPLC method permitted the highly sensitive and 
accurate determination of serum (or plasma) Pls by using a radioactive iodine (125I), and 
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removing interfering substances with HPLC. The primary advantage of this method enabled 
to measure PlsCho and PlsEtn separately. 125I-HPLC method has been markedly improved by 
introducing a quantitative standard (Q.S.) and online detection with flow Ǆ-counter. 1-Alkenyl 
2,3-cyclic glycerophosphate was decided as Q.S. in view of both the same quantitative 
property of Pls and the proper retention time in the HPLC elution profile (Fig.5, 6).  
 
Fig. 5. Chemical structure of 1-Alkenyl 2,3-cyclic glycerophosphate (Q.S.) 
 
Fig. 6. A typical HPLC elusion profile of Pls and Q.S. detected with flow Ǆ-counter 
Online detection with flow Ǆ-counter permitted more precise and safe measurement of Pls-
related radio activity. The improved method has been fully validated in terms of selectivity, 
sensitivity, linearity, precision, accuracy, and has applied to the determination of human 
serum Pls. To minimize diffusion of radioactive contamination, the treatment column for 
HPLC waste fluid was prepared. The radioactive iodine adsorbents column reduced the 
radioactivity in waste fluid less than 500cpm/ml, even when 100 times sample injections. 
125I-HPLC method is useful as a continious auto-analytical system for a routine diagnostic 
test of human serum (or plasma) Pls. 
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2.3 Pls as a serum (plasma) biomarker 
We have focused on the antioxidant property of Pls, and the potential utility of serum Pls as 
a biomarker for oxidative stress and aging (Brosche, 1997). It is well known that the number 
and the capability of peroxisome reduce with aging (Poynter & Davnes, 1998), which may 
induce the reduction of Pls biosynthesis. Decreased antioxidant Pls level may lead to 
predominant oxidative status in redox balance, which may cause the diseases associated 
with aging or oxidative stress such as atherosclerosis, metabolic syndrome (MetS) and 
Alzheimer’s disease (Fig.7).  
Plasmalogen, aging, and oxidative stress
Oxidative  stress
Antioxidant
Peroxisome
Plasmalogen
Alzheimer’s Disease
Atherosclerosis
Metabolic syndrome
Inducer
Risk  factor
Ａｇｉｎｇ
 
Fig. 7. Hypothesis for Pls deficiency causing life-style related disease 
2.3.1 Serum (plasma) Pls 
Serum (plasma) Pls are mainly synthesized in and secreted by liver as a structural 
component of lipoproteins (Vance, 1990), and potentially prevent lipoprotein oxidation 
relevant to atherosclerosis probably due to the radical scavenging ability of vinyl-ether 
double bond (Engelmann et al., 1994; Zoeller et al, 1999). The profile of human serum 
(plasma) Pls is as follows. Pls concentration is 100-300 μM with the content ratio of 
PlsCho/PlsEtn ranging from 0.5 to 1.5. PlsCho represent approximately 5% of choline 
glycerophospholipid, while PlsEtn represent 50~60% of ethanolamine glycerophospholipid. 
Total phospholipids concentration is 2-4 mM in serum (plasma), including 60~75% choline 
glycerophospholipid and 2~5% ethanolamine glycerophospholipid. The distribution of Pls 
on lipoprotein classes shows higher proportion of HDL, LDL, and VLDL in the order 
(Wiesner et al., 2009). 
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2.3.2 Pls in serum (plasma) or red blood cells of normal subjects 
Pls levels in serum (plasma) or red blood cells of normal subjects have been determined 
with 125I-HPLC method in each generation (Table 1).  
 Blood serum or plasma Red blood cells 
 Young Middle-age Elderly Young 
 M F M F M F M F 
n 74 27 383 69 8 65 74 27 
Age 23.9 
±3.7 
22.7 
±3.9 
40.4 
±10.7 
34.8***
±10.3 
77.6 
±5.0 
72.3* 
±5.1 
23.9 
±3.7 
22.7 
±3.9 
PlsCho 
μM 
98.5 
±23.0 
115.2**
±24.5 
62.5 
±12.2 
69.8***
±13.0 
54.9 
±10.2 
54.7 
±11.2 
  
PlsEtn 
μM 
133.8 
±33.3 
142.9 
±38.7 
73.3 
±19.4 
71.0 
±20.5 
68.8 
±13.0 
68.5 
±16.6 
  
PlsCho+PlsEtn 
μM 
232.4 
±53.3 
258.1 
±61.2 
135.8 
±29.0 
140.7 
±29.8 
123.6 
±21.7 
123.2 
±25.5 
  
PlsCho/PlsEtn 
ratio 
0.75 
±0.12 
0.83* 
±0.14 
0.88 
±0.17 
1.04***
±0.28 
0.80 
±0.11 
0.82 
±0.15 
0.29 
±0.04 
0.29 
±0.03 
PL 
mM 
2.17
±0.34
2.14
±0.41
2.99 
±0.49
2.94
±0.33
3.28
±0.40
3.44
±0.38
  
PlsCho/PL
mol % 
4.6
±1.1
5.6*
±1.6
2.2
±0.4 
2.4***
±0.5
1.7
±0.3
1.6
±0.3
5.7 
±1.6 
6.5* 
±1.6 
PlsEtn/PL
mol % 
6.3
±1.8
6.9
±2.2
2.5
±0.6 
2.5
±0.7
2.1
±0.5
2.0
±0.5
19.2 
±4.6 
22.3* 
±4.8 
(PlsCho+PlsEtn)/PL
mol % 
10.9
±2.7
12.5
±3.7
4.6
±0.9 
4.8
±1.1
3.8
±0.8
3.6
±0.8
24.9 
±6.0 
28.8* 
±6.3 
Mean ±S.D., t-test between Male and Female in each generation, * p<0.05, ** p<0.01, *** p<0.001 
Table 1. Pls levels in serum (plasma) or red blood cells of normal subjects 
There were significant differences in almost all Pls parameters as well as age and total 
phospholipids (PL) among generations, except for PlsEtn level between middle-age and 
elderly. Pls in serum (plasma) is decreased with aging, especially substantial reduction was 
observed between young and middle-age. Interestingly, there were significant differences in 
PlsCho, PlsCho/PlsEtn ratio, and PlsCho/PL mol% between male (M) and female (F) of young 
and middle-aged normal subjects. However, the sex differences in PlsCho-related parameters 
disappeared in elderly normal subjects, suggesting that PlsCho biosynthesis may be partly 
affected by sex hormone like estrogen. Analysis of serum Pls of middle-aged normal subjects 
(n=452) showed a strong correlation between PlsCho and PlsEtn. Correlative analysis of 
PlsCho/PlsEtn ratio with PlsCho or PlsEtn suggested that the ratio is highly influenced by the 
variation of PlsEtn (Fig.8). PlsCho/PlsEtn ratio in red blood cells considerably differs from that 
in serum (plasma), indicating predominance of PlsEtn similarly to other many organs, tissues 
and cells. Both PlsCho/PL and PlsEtn/PL mol% in red blood cells of young female were 
significantly higher than those of young male, whereas only PlsCho/PL mol% in plasma of 
young female was significantly higher than that of young male. Analysis of Pls in plasma and 
red blood cells of young normal subjects (n=101) showed a strong correlation between PlsCho 
and PlsEtn in both specimens. Correlative analysis of PlsCho/PlsEtn ratio with PlsCho or 
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PlsEtn suggested that the ratio is highly influenced by the variation of PlsCho in the case of red 
blood cells (n.d.). There were no strong correlations (coefficient >0.3) in all Pls-related 
parameters between plasma and red blood cells (n.d.). 
 
Fig. 8. Relationship between PlsCho and PlsEtn 
Next, to investigate the clinical significance of serum Pls, correlative analyses were made of 
over 40 years old in middle-aged normal subjects (n=216). Their clinical and serum 
biochemical data are shown in Table 2. Almost all data showed in the normal range. Total 
Pls level was 137.0±29.6, and PlsCho/PlsEtn ratio was 0.87±0.19. 
n 
(M/F) 
216 
(195/21) 
Ǆ-GTP 
(U/l) 
58±58 Adiponectin 
(μg/mg) 
6.9±4.8 
Age 48.9±7.1 HDL-C 
(mg/dl) 
65±18 PlsCho 
(µM) 
62.7±12.9 
Body weight 
(kg) 
68.5±11.3 
 
LDL-C 
(mg/dl) 
124±27 PlsEtn 
(µM) 
74.2±19.6 
BMI 
(kg/m2) 
24.6±6.0 
 
TG 
(mg/dl) 
121±88 PlsCho+PlsEtn 
(µM) 
137.0±29.6 
Waist circumstance
(cm) 
83.0±8.9 
 
sdLDL 
(mg/dl) 
33.0±12.9 PlsCho/PlsEtn 
ratio 
0.87±0.19 
Systolic pressure 
(mmHg) 
126±14 
 
Glu 
(mg/dl) 
96±13 PL 
(mM) 
3.13±0.47 
Diastolic pressure 
(mmHg) 
81±11 
 
UA 
(mg/dl) 
6.2±1.5 PlsCho/PL 
(mol %) 
2.0±0.4 
GOT 
(U/l) 
25±10 
 
Hcy 
(μmol/l) 
11.0±5.0 PlsEtn/PL 
(mol %) 
2.4±0.6 
GPT 
(U/l) 
28±18 
 
hsCRP 
(μg/dl) 
78±67 (PlsCho+PlsEtn)/PL
(mol %) 
4.4±1.0 
Mean±S.D. 
Table 2. Clinical and biochemical data of middle-aged (≧40 years old) normal subjects 
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Correlative analyses revealed significant positive correlations between PlsCho and HDL-C 
(r = 0.714) or adiponectin (r = 0.314), and negative correlations between PlsCho and body 
weight (r = -0.334), waist circumference (r = -0.375), TG (r = -0.327), hsCRP (r = -0.250), 
respectively. Furthermore, PlsCho/PL mol% correlated with age (r = -0.266), systolic  
(r = -0.292) and diastolic pressure (r = -0.283), sdLDL-C (r = -0.458), UA (r = -0.255), as well 
as atherogenic index of plasma, calculated as log (TG/HDL-C) (r = -0.674) (Table 3). 
 n=216 correlation coefficient >0.25, p< 0.001 
 
Correlation 
coefficient 
age 
Body 
weight
Waist
size 
Systolic
pressure
Diastolic
pressure
HDL-C LDL-C sdLDL-C 
PlsCho -0.194 -0.334 -0.375 -0.134 -0.092 0.714 0.036 -0.224 
PlsEtn -0.023 -0.098 -0.118 0.020 0.125 0.408 0.120 0.016 
PlsCho+PlsEtn -0.100 -0.210 -0.240 -0.045 0.043 0.580 0.096 -0.086 
PlsCho/PlsEtn -0.140 -0.185 -0.196 -0.152 -0.241 0.167 -0.127 -0.242 
PL 0.052 0.066 0.068 0.252 0.293 0.285 0.301 0.367 
PlsCho/PL -0.266 -0.374 -0.408 -0.292 -0.283 0.506 -0.162 -0.458 
PlsEtn/PL -0.109 -0.157 -0.162 -0.128 -0.050 0.307 -0.033 -0.200 
(PlsCho+PlsEtn)/PL -0.191 -0.271 -0.290 -0.215 -0.162 0.427 -0.095 -0.337 
Correlation 
coefficient  
TG AIP Glu UA hsCRP
Adipo- 
nectin 
Hcy 
PlsCho -0.327 -0.576 -0.168 -0.151 -0.250 0.314 -0.233 
PlsEtn -0.038 -0.248 0.107 -0.012 -0.105 0.103 -0.194 
PlsCho+PlsEtn -0.166 -0.414 -0.001 -0.073 -0.178 0.205 -0.230 
PlsCho/PlsEtn -0.265 -0.241 -0.265 -0.119 -0.032 0.172 0.031 
PL 0.382 0.188 0.101 0.253 -0.068 -0.024 -0.063 
PlsCho/PL -0.542 -0.674 -0.236 -0.318 -0.226 0.319 -0.179 
PlsEtn/PL -0.271 -0.396 0.042 -0.172 -0.054 0.125 -0.158 
(PlsCho+PlsEtn)/PL -0.421 -0.561 -0.081 -0.255 -0.138 0.226 -0.183 
AIP; atherogenic index of plasma, calculated as log (TG/HDL-C) 
Table 3. Correlations between Pls and clinical or serum parameters of middle-aged (≧40) 
normal subjects 
Surprisingly, the correlation between PlsCho and HDL-C was stronger rather than that 
between PlsCho and PlsEtn (Fig.8, 9). Indeed, PlsCho preferentially distribute in HDL class 
compared to other lipoprotein fractions, but this fact cannot explain the strong correlation of 
PlsCho with HDL-C, because PlsEtn as well as PlsCho also show preferential distribution in 
HDL compartment. 
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Fig. 9. Relationship between Pls and HDL 
2.3.3 Pls in serum of CAD patients 
Pls levels in serum and lipoproteins were determined for the CAD patients referred for 
coronary angiography (n=50), and compared with those of patients with (≧75%) and 
without (<50%) significant stenosis (Table 4-1). Serum PlsCho was significantly decreased in 
CAD patients with ≧75% stenosis compared to patients without significant stenosis (<50%). 
Total phospholipids (PL), cholesterol (CH), triglyceride (TG), and protein content as well as 
Pls were determined in HDL and LDL fractions from patients’ serum. The ratios of Pls to 
each lipid (mol %) or protein (μmol/g) in lipoprotein particles were compared between 
patients with and without significant stenosis. The CAD patients with ≧75% stenosis 
showed significant reduction in PlsCho/protein ratio in both HDL and LDL, indicating that 
PlsCho content of each lipoprotein particle is entirely decreased. Concomitantly, tocopherols 
(V.E.), lipid-soluble antioxidant vitamin, levels in serum were determined, and compared 
with those of patients with (≧75%) and without (<50%) significant stenosis (Table 4-2). 
There were no significant differences in all tocopherol homolog between them. These results 
demonstrate the specific reduction in serum PlsCho in CAD patients, and show clinical 
utility of PlsCho as a serum biomarker for atherogenic status. 
Next, to investigate the relationship between Pls and other serum lipids or lipoproteins, 
correlative analyses were made of another CAD patients referred for coronary angiography 
(n=148). Their serum lipids and lipoproteins data including Pls are shown in Table 5.  
Interestingly, in addition to the strong correlation of PlsCho with HDL (Maeba et al., 2007), 
LDL particle size significantly correlated with PlsCho/PlsEtn ratio as well as TG and HDL-
C (Table 6). Small dense LDL (sdLDL) is well-known risk factor for atherosclerosis, and 
frequently observed in dyslipidemia of type-2 diabetes or MetS, which is characterized by 
low HDL and high TG (Nozue et al, 2007). As PlsEtn is presumably a precursor of PlsCho in 
biosynthetic pathway, PlsCho/PlsEtn ratio can be regarded as an indicator of transfer rate 
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from PlsEtn to PlsCho. Therefore, the cause or effect of declining transfer rate is assumed to 
be potentially related to the appearance of atherogenic sdLDL, but it is obscure how Pls are 
involved in the alteration of lipoprotein metabolism.  
 
Serum 
n (M/F) Age PlsCho PlsEtn PlsCho+PlsEtn 
stenosis µM µM µM ≧75% 30 (20/10) 67.8±10.3 39.2±10.5** 63.0±14.5 102.2±21.6 
<50% 20 (11/9) 61.0±17.7 49.0±12.4 66.9±18.8 115.9±25.7 
PlsCho/PlsEtn PL PlsCho/PL PlsEtn/PL (PlsCho+PlsEtn)/PL 
stenosis ratio mM mol % mol % mol % ≧75% 0.64±0.16 2.34±0.39 1.7±0.5 2.8±0.7 4.5±1.1 
<50% 0.78±0.28 2.59±0.54 1.9±0.4 2.6±0.7 4.5±0.9 
HDL 
PlsCho/PlsEtn PlsCho/PL PlsEtn/PL PlsCho/CH PlsEtn/CH 
stenosis ratio mol % mol % mol % mol % ≧75% 0.72±0.20 1.7±0.4 2.5±0.8 1.5±0.4 2.1±0.7 
<50% 0.86±0.34 1.7±0.4 2.2±0.6 1.5±0.3 1.9±0.6 
PlsCho/TG PlsEtn/TG PlsCho/protein PlsEtn/protein
stenosis mol % mol % µmol/g µmol/g ≧75% 14.6±8.2 21.4±13.8 11.3±3.5* 16.3±6.1 
<50% 12.7±4.8 16.1±7.1 14.2±4.9 17.7±6.4 
LDL 
PlsCho/PlsEtn PlsCho/PL PlsEtn/PL PlsCho/CH PlsEtn/CH 
stenosis ratio mol % mol % mol % mol % ≧75% 0.80±0.19 1.4±0.3 1.8±0.3 0.6±0.1 0.7±0.2 
<50% 0.94±0.30 1.6±0.4 1.8±0.4 0.7±0.2 0.7±0.2 
PlsCho/TG PlsEtn/TG PlsCho/protein PlsEtn/protein
stenosis mol % mol % µmol/g µmol/g ≧75% 3.3±1.4 4.2±1.8 24.9±6.0* 31.6±6.5 
<50% 4.3±1.9 4.8±2.2 29.8±7.3 32.8±7.4 
Mean±S.D. t-test between patients with and without significant stenosis, * p < 0.05 ** p < 0.01 
Table 4-1. Comparison of Pls levels in serum and lipoproteins between CAD patients with 
and without significant stenosis 
 
ǂ-Toc. ǃ-Toc. Ǆ-Toc. ǅ-Toc. 
stenosis μM μM μM μM ≧75% 29.6±5.8 0.6±0.2 1.9±0.7 0.1±0.1 
<50% 30.4±8.5 0.6±0.2 2.1±0.8 0.1±0.1 
Table 4-2. Comparison of V.E levels in serum between patients with and without significant 
stenosis 
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n (M/F) 148 (110/38) LDL size, nm 25.5 ± 0.5 
Age 65.2+12.2 MDA-LDL, U/l 105 ± 40 
CAD ≥75% stenosis 63.5% LP (a), mg/dl 26 ± 21 
PlsCho, μM 65 ± 18 TG, mg/dl 123 ± 80 
PlsEtn, μM 83 ± 33 LPL mass, ng/ml 42.7 ±13.3 
PlsCho +PlsEtn, μM 148 ± 50 apo A-I, mg/dl 119 ± 22 
PlsCho/PlsEtn ratio 0.83 ± 0.17 apo A-II, mg/dl 24 ± 6 
PL, mM 2.2 ± 0.4 apo B, mg/dl 102 ± 26 
TC, mg/dl 189 ± 40 apo B-48, mg/dl 6.9 ± 3.2 
LDL-C, mg/dl 119 ± 45 apo C-II, mg/dl 4 ± 2 
HDL-C, mg/dl 47 ± 11 apo C-III, mg/dl 9 ± 3 
RLP-C, mg/dl 5 ± 2 apo E, mg/dl 4.3 ± 1.3 
Mean±S.D. 
Table 5. Serum lipids and lipoproteins data of CAD patients 
Correlation 
coefficient 
RLP-C TG apo C-II HDL-C 
PlsCho/PlsEtn    
ratio 
LDL 
 particle size 
-0.452 -0.442 -0.431 0.415 0.402 
RLP-C; remnant-like particle-cholesterol 
Table 6. Parameters indicating significant strong correlation (coefficient > 0.4, p<0.001) with 
LDL particle size 
Most of the PlsCho in the plasma membrane are considered to be probably made by N-
methylation of PlsEtn in three steps by reaction with S-adenosylmethionine (AdoMet), 
rather than base exchange via exchange of choline (Cho) for ethanolamine (Etn) or serine 
(Ser), or the Kennedy pathway by reaction of cytidine monophosphate with PlsEtn 
(Horrocks et al, 1986). Serum PlsCho is also possibly derived from N-methylation of 
PlsEtn, catalyzed by a hepatocyte-specific enzyme, phosphatidylethanolamine N-
methyltransferase (PEMT) (Fig.10). Interestingly, PEMT knockout mice reveal that PEMT 
is required for hepatic secretion of triacylglycerol (TG) in very low density lipoproteins 
(VLDL) (Noga et al, 2002). This finding suggests that PlsCho may have an essential role in 
lipoprotein metabolism, because PEMT is responsible for ~30% of phosphatidylcholine 
(PC), major Cho-containing glycerophospholipid, formed in liver, while PlsCho is 
primarily made from PlsEtn probably via PEMT pathway. Furthermore, a polymorphism 
of the human PEMT gene is associated with diminished activity and may confer 
susceptibility to nonalcoholic fatty liver disease (NAFLD) (Song et al, 2005). This 
observation also suggests the importance of PlsCho in the transport of TG from liver, and 
the participation of the lack of PlsCho in the onset of metabolic syndrome (MetS), because 
NAFLD shares many features of the MetS, such as abdominal obesity, type 2 diabetes, 
dyslipidemia, and insulin resistance (Pacifico et al, 2011). Human PEMT gene is regulated 
by estrogen (Resseguie et al, 2007), which may explain the sex difference in serum levels 
www.intechopen.com
 
Serum Choline Plasmalogen is a Reliable Biomarker for Atherogenic Status 
 
255 
of PlsCho, despite no significant sex difference in serum levels of PC, and provide an 
evidence supporting the involvement of PEMT pathway in the synthesis of PlsCho. 
Moreover, a nutritional insufficiency in the methyl donor such as methionine or choline 
also causes lack of PlsCho and elevated homocysteine (Hcy), a risk factor for 
cardiovascular disease. These reports may provide the physiopathological basis for the 
validity of PlsCho as a biomarker for atherogenic status. 
 
Fig. 10. PEMT pathway for conversion of PlsEtn to PlsCho 
2.3.4 Intervention study of increasing serum Pls 
Myo-inositol (MI) is one of 9 isomers of inositol, and is the most abundant in nature 
including human body. Besides dietary intake, MI is synthesized from glucose in vivo. MI 
contributes to numerous functions as a precursor molecule, such as signal transduction 
through biosynthesis of inositol phospholipids, or ca2+ homeostasis through biosynthesis of 
inositol phosphates (Vanhaesebroeck et al., 2001). Moreover, MI itself plays an important 
role in normal functions of CNS as an organic osmolyte (Gullans & Verbalis, 1993), and also 
possibly involves in myelin formation (Berry et al., 2003). Pls are major component of myelin 
membranes, and essential for myelin formation and functions. In animal studies, oral 
administration of MI showed to increase Pls level in rat brain (Hoffman-Kuczynski & Reo, 
2004). Therefore, we have undertaken MI intervention study to investigate whether MI 
administration improves the dyslipidemia of MetS through facilitating Pls biosynthesis, and 
to explore the relationship between serum Pls and sdLDL. Clinical background of study 
subjects is shown in Table 7. Almost all subjects (n=17) were hyperlipidemia, and half of the 
subjects were diagnosed as MetS. Treatment of MI 5g daily for 1 week, followed by MI 10g 
daily for 1 week markedly reduced sdLDL, and significantly increased PlsCho as well as 
PlsCho/PL and blood glucose particularly for MetS subjects, without alteration in the levels 
of TG and HDL-C (Table 8). This result suggests that facilitating PlsCho biosynthesis 
potentially prevents from atherogenic status trough reducing sdLDL. The increase in Pls 
levels after MI treatment tended to be inversely proportional to the serum Pls levels before 
treatment (Fig.11). Serum Pls reached a plateau level of around 150 µM with MI treatment, 
which corresponds to the average level observed in normal subjects (Maeba et al., 2008). Pls 
biosynthesis is strictly regulated and the Pls levels in cells or tissues are physiologically kept 
constant (Liu et al., 2005). Our result appears to support these facts. 
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n (M/F) 17 (15/2) 
Age 43.6 ± 6.6 
Rate of obesity (BMI≧25) 65% 
Rate of hyperlipidemia 94% 
Rate of diabetes mellitus 18% 
Rate of hypertension 29% 
Rate of metabolic syndrome (MetS) 
(according to Japanese guideline*) 
47% 
Rate of current cigarette smoking 71% 
* Japanese criteria for MetS 
MetS is diagnosed when 1) plus more than two of the risk determinants among 2) – 4). 
 1) Waist circumstance: M≧85 cm, F≧90 cm 
 2) TG≧150 mg/dl and/or HDL-C<40 mg/dl 
 3) Systolic pressure≧130mmHg and/or Diastolic pressure≧85 mmHg 
 4) Fasting glucose≧110 mg/dl 
Table 7. Clinical background of study subjects 
 
 MetS (n = 8) non- MetS (n = 9) 
 before after before after 
BMI, kg/m2 29.3±3.0 29.7±3.7 (101.4) 25.3±2.3 25.2±2.6 (99.6) 
Waist circumstance, cm 99.6±6.3 99.9±9.1 (100.3) 85.0±4.6 82.9±4.0 (97.5) 
Systolic pressure, mmHg 136±13 140±26 (102.9) 132±11 125±9 (94.7) 
Diastolic pressure, mmHg 85±12 93±16 (109.4) 78±7 81±5 (103.8) 
Blood glucose, mg/dl 104.1±16.6 87.5±11.6 (84.1)* 96.2±18.6 97.7±17.4 (101.6) 
hsCRP, mg/dl 0.316±0.315 0.171±0.137 (54.1) 0.056±0.029 0.453±0.995 (808.9) 
apo A-I, mg/dl 121.3±21.6 122.5±15.2 (101.0) 147.6±14.7 146.0±16.4 (98.9) 
apo B, mg/dl 142.6±43.4 130.6±40.4 (91.6) 123.9±41.2 119.8±48.9 (96.7) 
apo E, mg/dl 6.0±1.2 5.8±1.3 (96.7) 4.3±1.5 4.2±2.0 (97.7) 
TG, mg/dl 230.1±89.9 239.5±142.4 (104.1) 151.8±87.4 135.3±100.8 (89.1) 
TC, mg/dl 261.9±69.7 246.1±62.6 (94.0) 256.3±66.1 249.3±85.2 (97.3) 
HDL-C, mg/dl 44.9±11.1 45.5±11.3 (100.9) 58.2±7.1 58.6±6.7 (100.7) 
LDL-C, mg/dl 185.5±71.4 166.1±68.0 (89.5) 174.4±58.0 164.4±70.8 (94.3) 
sdLDL-C, mg/dl 56.4±25.0 39.2±19.7 (69.5) 37.5±21.4 32.5±23.3 (86.7) 
PL, mM 2.8±0.5 2.8±0.5 (100.0) 2.9±0.5 2.8±0.8 (96.6) 
PlsCho, µM 40.9±9.0 51.5±3.6 (125.9)* 50.7±12.5 57.3±18.5 (113.0) 
PlsEtn, µM 44.9±13.1 53.9±6.7 (120.0) 56.6±20.6 60.0±20.3 (106.0) 
PlsCho+ PlsEtn, µM 85.8±20.3 105.4±8.6 (122.8)* 107.2±30.3 117.3±37.4 (109.4) 
PlsCho/PL, mol% 1.5±0.2 1.9±0.2 (130.3)*** 1.7±0.4. 2.1±0.5.(115.8) 
PlsEtn/PL, mol% 1.6±0.4 2.0±0.4 (124.4) 2.0±0.9 2.2±0.8 (106.4) 
(PlsCho+PlsEtn)/PL, mol% 3.1±0.5 3.9±0.6 (127.2)** 3.8±1.3 4.2±1.2 (111.0) 
PlsCho/PlsEtn ratio 0.94±0.23 0.97±0.12 (103.2) 0.94±0.21 0.98±0.17 (104.3) 
Values are mean±S.D., and values in parentheses are relative percentage to each value before treatment. 
t-test between before and after treatment, * p < 0.05, ** p < 0.01, *** p < 0.001 
Table 8. Effect of myo-inositol treatment on clinical and serum biochemical parameters of the 
hyperlipidemic subjects with (MetS) and without metabolic syndrome (non-MetS) 
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Fig. 11. Relationship between the gain rate of Pls after MI treatment and serum Pls levels 
before treatment 
3. Conclusion 
We have established auto-analytical 125I-HPLC system for a routine diagnostic test of human 
serum (or plasma) Pls. We have applied the system to the determination of serum (or 
plasma) Pls from normal subjects and CAD patients, and found that serum (or plasma) 
PlsCho is a novel and reliable biomarker for MetS and atherosclerosis. Intervention study of 
increasing PlsCho by MI treatment demonstrated clinical utility of PlsCho as a serum (or 
plasma) biomarker for atherogenic status. Improvement of PlsCho deficiency is important 
for preventing from life-style related disease associated with aging and oxidative stress. MI 
intake is one of the effective ways to enhance Pls biosynthesis. 
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